News
-
-
PRESS RELEASE
Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome
Telomir-1 treatment shows promising results in reversing aging hallmarks in a rare genetic disorder. Findings include restored gene control, extended telomere length, muscle and weight recovery, reduced oxidative stress, and 100% survival -
PRESS RELEASE
Orogen Royalties Announces Filing and Mailing of the Management Information Circular in Connection with the Annual General and Special Meeting of Shareholders
Orogen Royalties Inc. announces annual general meeting for shareholders to vote on proposed arrangement with Triple Flag. Shareholder support recommended. Contact Laurel Hill Advisory Group for assistance -
-
PRESS RELEASE
ViGeneron Rebrands as VeonGen Therapeutics and Announces FDA Rare Pediatric Disease Designation and Clinical Progress for Lead Gene Therapy VG801 in Stargardt Disease
VeonGen Therapeutics (formerly ViGeneron) announces FDA Rare Pediatric Disease Designation and clinical progress for lead gene therapy VG801 in Stargardt Disease, advancing genetic medicine in ophthalmology and beyond -
PRESS RELEASE
Brenmiller Energy CEO Provides Update On Milestones Powering Progress
Brenmiller Energy provides shareholder update highlighting strategic projects including the SolWinHy Project receiving €25 million in funding and the upcoming milestone with Tempo. The company explores opportunities in nuclear energy for AI and data centers -
-
-
-
